Stephen C. Bain

TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.

TL;DR: Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes and early nephropathy, and these findings support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in people with conditions that place them at high risk for cardiovascular events.

TL;DR: In this article, the authors described linkage and association of type 1 diabetes to the CTLA-4 gene (cytotoxic T lymphocyte associated-4) on chromosome 2q33 (designated IDDM12), which is a strong candidate gene for T cell mediated autoimmune disease because it encodes a T cell receptor that mediates T cell apoptosis and is a vital negative regulator of T cell activation.

TL;DR: Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes in this trial, with the limitation that withdrawn individuals were not followed up after discontinuation.

TL;DR: A genome-wide scan of 93 affected sibpair families from the UK indicated a similar genetic basis for human type 1 diabetes, with the major genetic component at the MHC locus (IDDM1) explaining 34% of the familial clustering of the disease.